Influenza viruses of genera A and B usually cause uncomplicated febrile upper respiratory tract infections with respiratory symptoms in healthy individuals. In the case of severe courses, however, complications can occur, such as the development of primary influenza pneumonia or secondary bacterial infection, which can lead to the death of the patient.

In Germany, two classes of drugs, M2 ion channel blockers and neuraminidase inhibitors, are approved for the treatment of influenza. However, the great genetic flexibility of the viruses means that there is a risk of rapid development of resistance. For example, some subtypes have already developed complete resistance to M2 ion channel blockers. Numerous resistances have also been described against neuraminidase inhibitors. Therefore, novel agents for the treatment of influenza infections are urgently needed. 

The primary goal of the project is to identify novel drug compounds for the treatment of influenza across subtypes.